Dublin, Dec. 05, 2019 (GLOBE NEWSWIRE) — The “Global Metabolic Partnering 2014-2019: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
Global Metabolic Partnering 2014 to 2019 provides the full collection of Metabolic disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.
Global Metabolic Partnering 2014 to 2019 includes:
- Trends in Metabolic dealmaking in the biopharma industry since 2014
- Analysis of Metabolic deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Metabolic deal contract documents
- Comprehensive access to over 800 Metabolic deal records
- The leading Metabolic deals by value since 2014
- Most active Metabolic dealmakers since 2014
The report includes deals for the following indications:
Acromegaly, Addison’s disease, Cirrhosis, Cushing’s syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.
Available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Chapter 1 – Introduction
Chapter 2 – Trends in Metabolic dealmaking
2.2. Metabolic partnering over the years
2.3. Metabolic partnering by deal type
2.4. Metabolic partnering by industry sector
2.5. Metabolic partnering by stage of development
2.6. Metabolic partnering by technology type
2.7. Metabolic partnering by therapeutic indication
Chapter 3 -Financial deal terms for Metabolic partnering
3.2. Disclosed financials terms for Metabolic partnering
3.3. Metabolic partnering headline values
3.4. Metabolic deal upfront payments
3.5. Metabolic deal milestone payments
3.6. Metabolic royalty rates
Chapter 4 – Leading Metabolic deals and dealmakers
4.2. Most active in Metabolic partnering
4.3. List of most active dealmakers in Metabolic
4.4. Top Metabolic deals by value
Chapter 5 – Metabolic contract document directory
5.2. Metabolic partnering deals where contract document available
Chapter 6 – Metabolic dealmaking by therapeutic target
6.2. Deals by Metabolic therapeutic target
Appendix 1 – Directory of Metabolic deals by company A-Z since 2014
Appendix 2 – Directory of Metabolic deals by deal type since 2014
Appendix 3 – Directory of Metabolic deals by stage of development since 2014
Appendix 4 – Directory of Metabolic deals by technology type since 2014
For more information about this report visit https://www.researchandmarkets.com/r/dxzi42
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Written by .
View the original article at here.